Oral contraceptives: considerations of safety in nonclinical distribution.
D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced; D003276:Contraceptives, Oral / Q000009:adverse effects* / Q000494:pharmacology; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian / Q000187:drug effects; D004739:England; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D005705:Gallbladder Diseases / Q000139:chemically induced; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000139:chemically induced; D007565:Jaundice / Q000139:chemically induced; D007774:Lactation / Q000187:drug effects; D008428:Maternal Mortality; D008875:Middle Aged; D004366:Nonprescription Drugs; D011247:Pregnancy; D011655:Pulmonary Embolism / Q000139:chemically induced; D013924:Thrombophlebitis / Q000139:chemically induced; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced
D003276:Contraceptives, Oral; D004967:Estrogens; D004366:Nonprescription Drugs